Analysts expect that OvaScience Inc (NASDAQ:OVAS) will report earnings of ($0.29) per share for the current quarter, Zacks reports. Three analysts have made estimates for OvaScience’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.32). OvaScience reported earnings per share of ($0.64) in the same quarter last year, which would indicate a positive year over year growth rate of 54.7%. The company is expected to report its next earnings report on Thursday, March 1st.
According to Zacks, analysts expect that OvaScience will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.47). For the next fiscal year, analysts forecast that the company will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.92). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover OvaScience.
OvaScience (NASDAQ:OVAS) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.15. OvaScience had a negative return on equity of 68.71% and a negative net margin of 20,090.13%.
OVAS has been the topic of several analyst reports. Zacks Investment Research lowered OvaScience from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of OvaScience in a report on Monday, November 6th.
A number of institutional investors and hedge funds have recently modified their holdings of the business. GMT Capital Corp acquired a new stake in OvaScience in the third quarter valued at approximately $1,138,000. Sabby Management LLC grew its holdings in OvaScience by 20.2% in the second quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock valued at $795,000 after purchasing an additional 85,525 shares during the period. Broadfin Capital LLC acquired a new stake in OvaScience in the second quarter valued at approximately $429,000. Susquehanna International Group LLP grew its holdings in OvaScience by 87.2% in the second quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 52,538 shares during the period. Finally, Zacks Investment Management acquired a new stake in OvaScience in the second quarter valued at approximately $140,000. 55.06% of the stock is currently owned by institutional investors.
OvaScience (NASDAQ:OVAS) traded down $0.05 during trading on Tuesday, reaching $1.09. The company had a trading volume of 278,992 shares, compared to its average volume of 1,013,895. OvaScience has a 12-month low of $1.07 and a 12-month high of $2.05.
ILLEGAL ACTIVITY NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/0-29-earnings-per-share-expected-for-ovascience-inc-ovas-this-quarter.html.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Get a free copy of the Zacks research report on OvaScience (OVAS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.